Drugs / AV-1959D
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05642429 Comparator | Feb 2023 → Jul 2026 overdue | Alzheimer disease | Institute for Molecular Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-1959D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05642429 ↗ |
| Modality | Vaccine | “A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.” NCT05642429 ↗ |